Plain-English translation of NCT07420790 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying how well Venetoclax plus Decitabine (a newer two-drug combination) works for older adults aged 60–75 with acute myeloid leukemia who are eligible for stem cell transplant. They will compare this medication against historical records of patients who received standard chemotherapy. The study will also use artificial intelligence to help predict how well the treatment works.
Older adults with acute myeloid leukemia have limited treatment options, and doctors need better ways to decide which treatments work best for them. This study aims to validate whether this newer medication approach is more effective than standard treatments by learning from real-world patient data.
You likely qualify if…
You likely don't qualify if…
This is primarily a data study, so you would not receive the medication as part of this trial. Researchers will collect and review your medical records from your actual leukemia treatment (whether you received the newer two-drug combination or standard chemotherapy). Your anonymized data will then be used to train an artificial intelligence model that helps predict treatment outcomes for other patients like you.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
Italy
Sponsor
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Enrollment target
~1,941 participants
Started
February 2026
Primary completion
July 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Domenico Russo, MD
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.